Ann: Planned CEO transition to support US growth opportunities, page-3

Two interesting but progressive announcements in a matter of days.

I suspect Management/Board is betting on funding the final payment without a CR or triggering PFG.

Perhaps they needed to show Syneos they were good for the cash with some numbers from Q3.

This choking of momentum could be the likes Regal/PVM/Jencay who might have been hoping to be a lender at these levels.

If the March revenues are $20M+ and June $22M+, then it appears Management are confident in navigating the next few quarters.

MDR now has two disparate teams - AU supporting MedAdvisor and US supporting Adheris.

The message here suggests AU has enough of a resource pool to be supported, but the US needs a local Exec with Big Pharma, Pharmacy and Government contacts, something that the AU team probably lacks.

I wouldn't be surprised if the March quarter announcement includes an increased revenue guidance for FY22.